Short communication, Note

https://doi.org/10.11613/BM.2019.010901

Effects of different anticoagulants on glycated albumin quantification

Graziella Bonetti ; Central Clinical Chemistry Laboratory, ASST Spedali Civili, Brescia, Italy
Nicola Di Gaetano ; Instrumentation Laboratory - A Werfen Company, R&D Department, Milano, Italy
Renata Paleari ; Department of Pathophysiology and Transplantation, Centre for Metrological Traceability in Laboratory Medicine (CIRME), Università degli Studi di Milano, Milano, Italy
Ferruccio Ceriotti ; Clinical Laboratory, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milano, Italy

Abstract

Introduction: In the last 20 years glycated albumin (GA) measurement has been demonstrated to be a reliable glycation marker and recently as
the most innovative one in western countries. Glycated albumin has been already adopted by some Asian countries due to its usefulness in diabetes
screening. The aim of the present study was to investigate for the first time the effects of different anticoagulants on GA assay.
Materials and methods: From each of 60 patients a serum tube and K3EDTA, Li-Heparin and NaF-EDTA containing tubes were collected. All tubes
were from Sarstedt (Verona, Italy). Glycated albumin was measured in duplicate in each sample tube in a single analytical run with quantILab glycated
albumin (Instrumentation Laboratory SpA - A Werfen Company, Milan, Italy) on Architect c8000 analyser (Abbott SRL, Rome, Italy). Comparison
of GA% in evaluated tubes was made by paired Wilcoxon test.
Results: Median and interquartile range GA% concentrations were 15.4% (13.2 - 19.1) in serum, 15.7% (13.6 - 19.9) in K3EDTA, 15.6% (13.3 - 19.7) in
Li-heparin and 15.5% (13.1 - 19.3) in NaF-EDTA samples, respectively. Glycated albumin mean relative bias respect to serum was within desirable bias
derived from biological variation studies (± 2.9%) when K3EDTA (+ 2.8%), Li-heparin (+ 0.9%) or NaF-EDTA (+ 0.1%), were used as anticoagulants.
Conclusions: Our results demonstrate that the GA% assay is not affected by relevant interferences when K3EDTA, Li-heparin or NaF-EDTA are used
as anticoagulants, so they can be used interchangeably without a relevant impact on the clinical use of the test.

Keywords

preanalytical phase; serum albumin; diabetes mellitus; anticoagulants

Hrčak ID:

213859

URI

https://hrcak.srce.hr/213859

Publication date:

15.2.2019.

Visits: 1.627 *